Study details
Enrolling now
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Eli Lilly and Company
NCT IDNCT06948422ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
974
Study length
about 2.4 years
Ages
18+
Locations
30 sites in AZ, CA, CT +15
What this study is about
Researchers are testing a treatment called orforglipron to see if it helps lower blood pressure in people who have both hypertension and obesity or overweight. The trial will last for 883 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Orforglipron
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Cardiology / Heart